Blosozumab Biosimilar - Research Grade

Human

SOST

>1mg/ml

Human IgG4 (S228P/KDel)-Kappa

Romosozumab Biosimilar - Research Grade (ICH5108), Resugosbart Biosimilar - Research Grade (ICH5817), Setrusumab Biosimilar - Research Grade (ICH5857)

https://www.imgt.org/mAb-DB/

ICH3002

Q9BQB4

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of blosozumab, an anti-sclerostin (SOST) antibody, supplied for research use only. It is built around blosozumab's target, human sclerostin, and is provided as a full-length human IgG4 (S228P stabilized hinge; C-terminal Lys removed) kappa immunoglobulin. It is not the clinical drug and is not intended for human or veterinary use. The format is well suited to bench research: as a positive/reference control in sclerostin binding and neutralization assays, for benchmarking or characterizing other anti-SOST antibodies, for epitope-competition and pharmacology comparisons, for Wnt-pathway reporter and osteoblast differentiation studies, and as a tool reagent in assay development, ELISA/SPR/BLI standardization, and preclinical model work. It is offered at research grade with low endotoxin (typically less than 1 EU/mg, with an ultra-low-endotoxin option below 0.5 EU/mg) and can be produced at bulk milligram-to-gram scale to support screening campaigns and reproducible, batch-consistent studies. Sclerostin (SOST; UniProt Q9BQB4) is a secreted glycoprotein of the DAN/cerberus family, expressed predominantly by osteocytes embedded in bone. It is a key negative regulator of bone formation. Sclerostin binds the co-receptors LRP5 and LRP6 and antagonizes canonical Wnt/beta-catenin signaling, thereby restraining osteoblast activity, proliferation, and survival and dampening bone matrix deposition. It also modulates BMP signaling. Its activity is regulated mechanically and hormonally; mechanical loading and parathyroid hormone suppress SOST expression, permitting Wnt-driven bone accrual. Loss-of-function mutations cause the high-bone-mass disorders sclerosteosis and van Buchem disease, establishing sclerostin as a bone-mass brake. Because inhibiting sclerostin releases Wnt signaling and promotes bone formation, it is a validated therapeutic target in osteoporosis and a widely studied node in skeletal biology.

Sclerostin

Detects human SOST

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

S228P

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.